Cite
HARVARD Citation
Gandhi, S. et al. (n.d.). 321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer. Journal for immunotherapy of cancer. p. A197. [Online].